Loading…
ResMed Inc. is projected to rise to $242.77 by 2027, a +16% move from its current price of $208.96. RMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $204.92 | $209.03 | $213.22 | +0.03% |
| Aug 1 | $203.31 | $209.09 | $215.05 | +0.06% |
| Aug 2 | $202.09 | $209.16 | $216.48 | +0.10% |
| Aug 3 | $201.08 | $209.23 | $217.70 | +0.13% |
| Aug 4 | $200.21 | $209.30 | $218.80 | +0.16% |
| Aug 5 | $199.43 | $209.36 | $219.80 | +0.19% |
| Aug 6 | $198.72 | $209.43 | $220.73 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $198.72 | $209.43 | $220.73 | +0.23% |
| Week 2 | $194.88 | $209.90 | $226.09 | +0.45% |
| Week 3 | $192.08 | $210.38 | $230.42 | +0.68% |
| Week 4 | $189.83 | $210.85 | $234.21 | +0.91% |
| Week 5 | $187.91 | $211.33 | $237.67 | +1.13% |
| Week 6 | $186.24 | $211.81 | $240.89 | +1.36% |
| Week 7 | $184.74 | $212.29 | $243.94 | +1.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ResMed Inc. is a healthcare company that develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.
ResMed was founded in 1989 and is headquartered in San Diego, California, providing a range of sleep diagnostics and therapy solutions. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
In addition, the company offers Brightree solutions for home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers.
ResMed Inc. (RMD) is currently priced at $198.57 and has a market capitalization of $28.8B, placing it with a rank of 472 by market cap. The stock displays a bearish near-term technical backdrop while showing implied upside in the longer horizon based on the available forecast data.
The near-term picture shows the stock trading with RSI of 50, and it sits above the 50-day simple moving average of $200.02 while remaining below the 200-day moving average of $236.46. Immediate support is listed at $182.82 and resistance at $219.75. The 30-day price range spans from $172.85 to $228.11, highlighting recent volatility within that window.
Looking ahead, the 2026 forecast presents an average price equal to the current price at $198.57 with a potential range from $182.82 to $262.13, implying a neutral near-term stance before farther upside develops in subsequent years.
A major floor 17.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 14.1% above — clearing it would confirm fresh momentum.
Key RMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $198.42 | Buy | $201.49 | Buy |
| MA 10 | $198.68 | Buy | $200.09 | Buy |
| MA 20 | $202.01 | Buy | $199.90 | Buy |
| MA 50 | $198.82 | Buy | $202.43 | Buy |
| MA 100 | $211.23 | Sell | $211.77 | Sell |
| MA 200 | $232.96 | Sell | $224.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.22 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 73.96 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.35 | Buy |
| ROC (12) | 2.50 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 63.47 | Neutral |
| Momentum (10) | 15.95 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 201.10 | Buy |
| ADX (14) | 12.55 | Neutral |
| ATR (14) | 4.19 | Info |
The 30-day technical picture is bearish at the moment, with momentum not yet turning positive. Traders may monitor for a shift in sentiment as prices approach key levels.
RSI14 stands at 50, while the price sits above the SMA50 of $200.02 but remains below the SMA200 of $236.46. Immediate support is at $182.82 and resistance at $219.75, defining a narrow range around the current price.
The 30-day range runs from $172.85 to $228.11, reflecting ongoing volatility within a relatively wide band for the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $182.82 | $208.96 | $276.71 | 0% | Neutral | |
| $198.38 | $242.77 | $310.95 | +16% | Neutral | |
| $218.30 | $272.53 | $359.10 | +30% | Bullish | |
| $227.54 | $288.73 | $389.01 | +38% | Bullish | |
| $223.99 | $288.33 | $395.84 | +38% | Bullish | |
| $259.96 | $338.98 | $473.11 | +62% | Bullish | |
| $297.74 | $392.91 | $556.57 | +88% | Bullish | |
| $321.46 | $428.97 | $615.90 | +105% | Bullish | |
| $354.20 | $477.68 | $694.41 | +129% | Bullish | |
| $360.41 | $490.95 | $722.01 | +135% | Bullish | |
| $533.93 | $760.74 | $1,174.83 | +264% | Bullish | |
| $840.04 | $1,289.94 | $2,141.39 | +517% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $182.82 | $208.96 | $245.16 | +0.00% |
| August 2026 | $185.10 | $216.10 | $257.32 | +3.42% |
| September 2026 | $183.24 | $215.19 | $258.72 | -0.42% |
| October 2026 | $183.26 | $216.24 | $261.98 | +0.49% |
| November 2026 | $188.11 | $222.85 | $271.68 | +3.06% |
| December 2026 | $189.82 | $225.69 | $276.71 | +1.27% |
Click any year to see its month-by-month RMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RMD is projected to trade between $182.82 and $276.71, averaging $208.96 — a potential gain of 0% from today's $208.96. Price action looks broadly range-bound.
ResMed Inc.'s 2027 outlook centres on $242.77, within a $198.38 to $310.95 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, RMD could reach as high as $359.10, with a base case around $272.53 and support toward $218.30 — roughly +30% from $208.96. Momentum favours further upside here.
Expect RMD to range from $227.54 to $389.01 through 2029. The $288.73 average target implies a +38% move from current prices. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The RMD price prediction for 2030 points to an average of $288.33 (low $223.99, high $395.84) — a potential gain of +38% on today's $208.96. Momentum favours further upside here.
In 2031, RMD is projected to trade between $259.96 and $473.11, averaging $338.98 — a potential gain of +62% from today's $208.96. That is up +18% on the projected 2030 average. Buyers look set to stay in control over this stretch.
ResMed Inc.'s 2032 outlook centres on $392.91, within a $297.74 to $556.57 range. That is up +16% on the projected 2031 average. That marks a +88% change versus current levels. Momentum favours further upside here.
By 2033, RMD could reach as high as $615.90, with a base case around $428.97 and support toward $321.46 — roughly +105% from $208.96. Buyers look set to stay in control over this stretch.
Expect RMD to range from $354.20 to $694.41 through 2034. The $477.68 average target implies a +129% move from current prices. That is up +11% on the projected 2033 average. Momentum favours further upside here.
The RMD price prediction for 2035 points to an average of $490.95 (low $360.41, high $722.01) — a potential gain of +135% on today's $208.96. Buyers look set to stay in control over this stretch.
In 2040, RMD is projected to trade between $533.93 and $1,174.83, averaging $760.74 — a potential gain of +264% from today's $208.96. That is up +55% on the projected 2035 average. Momentum favours further upside here.
ResMed Inc.'s 2050 outlook centres on $1,289.94, within a $840.04 to $2,141.39 range. That is up +70% on the projected 2040 average. That marks a +517% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RMD today (≈ 4.785605 RMD) could be worth
$6,173.16
+$5,173.16 (+517%) by 2050 · US Dollar
Based on the average projected RMD price of $1,289.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RMDwould be worth at today's price.
$1,000 invested in RMD on Jul 28, 2025 (≈ 3.656307 RMD) would be worth
$764.02
-$235.98 (-23.6%) today · 0.76× · US Dollar
Based on a RMD entry price of $273.5 vs. today's $208.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $195.8 | $1,067.21 | +6.7% |
| 1 month ago | $198.43 | $1,053.07 | +5.3% |
| 3 months ago | $211.93 | $985.99 | -1.4% |
| 6 months ago | $257.61 | $811.15 | -18.9% |
| 1 year ago | $273.5 | $764.02 | -23.6% |
| All time (5.0y) ago | $268.63 | $777.87 | -22.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RMD forecast.
Our base-case forecast reaches $420.00 around 2033.
Implied market cap at $420.00: $60.92B
The multi-year forecast envisions a bullish trajectory from the late 2020s through 2050, with rising average prices and substantial upside potential. Starting in 2027 the averages rise from $228.30 (2027) to higher levels, with 2030 showing an average of $256.91 and a max of $356.21, yielding a 29.4% ROI and a bullish sentiment.
By 2040 the average price is forecast at $619.08 with a max of $970.59 and a strong 211.8% ROI, continuing the bullish trend. The longer-range view extends to 2050, where the average is projected at $1,006.30 and a max of $1,701.00, for a 406.8% ROI. The year-by-year path includes notable steps such as 2031 average $297.40 (ROI 49.8%) and 2032 average $333.46 (ROI 67.9%), reflecting sustained upside potential.
These estimates carry inherent uncertainty and are not a guarantee of future results. They illustrate a potential growth trajectory under the provided assumptions, with higher upside potential in the later years and substantial variability across years.
Tap a question to reveal the answer.
2030: min $198.05, avg $256.91, max $356.21; ROI 29.4%; sentiment BULLISH.
The forecast shows bullish momentum in the later years, with rising averages (e.g., 2027 avg $228.30; 2040 avg $619.08; 2050 avg $1,006.30) and meaningful ROI (up to 406.8% by 2050). These are estimates, not guarantees.
Yes. For 2031, the forecast lists min $226.13, avg $297.40, max $419.51 with ROI 49.8 and sentiment BULLISH.
The 30-day range is $172.85 to $228.11.
Current price is $198.57. Market cap is $28.8B and the rank is 472.
ResMed Inc. Community Discussion
0Share your ResMed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.